Sebia acquires ORGENTEC Diagnostika

June 30, 2021

Sebia announced the acquisition of ORGENTEC Diagnostika from Water Street Healthcare Partners, a strategic investor focused on healthcare, for an undisclosed amount. The transaction is expected to close in the next quarter.

Based in Mainz, Germany, ORGENTEC Diagnostika focuses on the development, production, and marketing of diagnostic tests to detect autoimmune and blood diagnostics and treatment-associated monitoring. Clinical areas include inflammatory rheumatic diseases, thrombosis diagnostics, blood diagnostics for the serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and diabetes diagnostics.

The company also operates two fully integrated business divisions:

          Corgenix Medical Corporation, based in Broomfield, CO, offers a broad range of products and capabilities for the pharmaceutical industry in the development, tech transfer, registration, manufacturing and commercialization of specialty diagnostics tests.

          AROTEC Diagnostics has been producing and delivering components to the autoimmune diagnostic industry since its incorporation in 1996. Based in Wellington, New Zealand, AROTEC supplies premium reagents to both IVD companies and research and academic groups around the world. 

Visit Sebia for more news